Dr. Kenneth Mahaffey, MD

• Cardiology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Arizona / College Of Education

  Medical School, 1992

• Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial, 2021-08-20

• The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX, 2015-09-23

• Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, 2018-07-26

• Lessons Learned in the Apple Heart Study and Implications for the Data Management of Future Digital Clinical Trials, 2022-06-12

• 4243 Developing clinical research units to improve quality, efficiency, and cost effectiveness within an academic institution, 2020-06-01

• World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial, 2021-09-13

• Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A pooled analysis of 9,259 Deaths in 9 trials, 2019-02-12

• Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial, 2022-05-27

• Data monitoring committees: Promoting best practices to address emerging challenges, 2017-02-01

• Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program, 2019-03-12

• Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), 2020-04-16

• Cinacalcet, Dialysate Calcium Concentration, and Cardiovascular Events in the EVOLVE trial, 2015-11-13

• Non-Central Nervous System Systemic Embolism in Patients with Atrial Fibrillation: Results from ROCKET AF, 2017-04-25

• Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP), 2022-06-28

• Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY, 2021-03-19

• Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program, 2019-08-10

• Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes The ORBIT-AF II Registry, 2018-07-14

• The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX, 2019-06-29

• Lack of Concordance between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry, 2014-03-29

• Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program, 2021-03-13